In another reports, TGF-β receptor II (TGFBR2) ablation by genome-editing technologies upgraded anti-tumor efficacy of anti-mesothelin CAR-T cells against ovarian cancer cells, which mainly mediated by a reduction in the activated Treg conversion and circumventing CAR-T cells depletion [179]. This evidence concerns the gene MSLN and neoplasm.